JCI Insight (Feb 2021)

HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy

  • Eva M. Stevenson,
  • Adam R. Ward,
  • Ronald Truong,
  • Allison S. Thomas,
  • Szu-Han Huang,
  • Thomas R. Dilling,
  • Sandra Terry,
  • John K. Bui,
  • Talia M. Mota,
  • Ali Danesh,
  • Guinevere Q. Lee,
  • Andrea Gramatica,
  • Pragya Khadka,
  • Winiffer D. Conce Alberto,
  • Rajesh T. Gandhi,
  • Deborah K. McMahon,
  • Christina M. Lalama,
  • Ronald J. Bosch,
  • Bernard Macatangay,
  • Joshua C. Cyktor,
  • Joseph J. Eron,
  • John W. Mellors,
  • R. Brad Jones,
  • for the AIDS Clinical Trials Group A5321 Team

Journal volume & issue
Vol. 6, no. 3

Abstract

Read online

Antiretroviral therapies (ARTs) abrogate HIV replication; however, infection persists as long-lived reservoirs of infected cells with integrated proviruses, which reseed replication if ART is interrupted. A central tenet of our current understanding of this persistence is that infected cells are shielded from immune recognition and elimination through a lack of antigen expression from proviruses. Efforts to cure HIV infection have therefore focused on reactivating latent proviruses to enable immune-mediated clearance, but these have yet to succeed in reducing viral reservoirs. Here, we revisited the question of whether HIV reservoirs are predominately immunologically silent from a new angle: by querying the dynamics of HIV-specific T cell responses over long-term ART for evidence of ongoing recognition of HIV-infected cells. In longitudinal assessments, we show that the rates of change in persisting HIV Nef-specific responses, but not responses to other HIV gene products, were associated with residual frequencies of infected cells. These Nef-specific responses were highly stable over time and disproportionately exhibited a cytotoxic, effector functional profile, indicative of recent in vivo recognition of HIV antigens. These results indicate substantial visibility of the HIV-infected cells to T cells on stable ART, presenting both opportunities and challenges for the development of therapeutic approaches to curing infection.

Keywords